Tractament del càncer colorectal metastàtic amb anticossos anti-VEGF o anti-EGFR en primera línia: informe d’avaluació de resultats
Abstract
Colorectal cancer (CRC) is the second most common cancer in the population as a whole and one of the leading causes of death in Europe. At the time of diagnosis, it is estimated that 25% of patients will metastasize and almost 50% of patients with CRC will develop it. Some studies estimate an overall survival (OS) of approximately 30 months in patients with treatment for metastatic colorectal cancer (mRC), much higher than years ago when only chemotherapy (QT) was available conventional. Targeted therapy drugs have been marketed for first-line treatment, such as monoclonal antibodies: bevacizumab (anti-VEGF [vascular endothelial growth factor]), cetuximab, and panitumumab (anti-EGFR [ of epidermal growth]).
Keywords
Metastatic colorectal cancer; Anti-VEGF monoclonal antibodies; Anti-EGFR monoclonal antibodies
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tractament del càncer colorectal metastàtic amb anticossos anti-VEGF o anti-EGFR en primera línia: informe d’avaluació de resultats. Barcelona: Servei Català de la Salut; 2020.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/5441This item appears in following collections
The following license files are associated with this item: